For example, immune checkpoint inhibitors (ICIs) have been approved only for patients with microsatellite instability [2], whereas dual anti-BRAF and anti-EGFR combinations are only available for metastatic colorectal cancers with the BRAF V600E mutation [3]. The gene discussed is BRAF; the disease is metastatic colorectal cancer.